Core Viewpoints - The company holds a leading position in the domestic heart valve intervention field, with TAVR products showing positive clinical feedback and rapid market share growth since commercialization [1][6] - The company has a comprehensive product pipeline in aortic, mitral, and tricuspid valve treatments, which continues to strengthen its leadership in the heart valve sector [1][6] - The company anticipates three major products to be approved and commercialized in China between the end of 2025 and 2026, contributing to a rapid recovery in overall performance [1][6] Event Summary - On December 5, 2025, the company announced that Chairman Dr. Zhang Yi plans to invest up to HKD 15 million in purchasing company shares on the open market [1] - This share buyback reflects Dr. Zhang's confidence in the company's long-term development potential and intrinsic value [1] Product Development and Pipeline - The company has made significant progress in its product pipeline, with multiple innovative products expected to achieve commercialization, including the GeminiOne transcatheter edge-to-edge repair system and the ReachTactile robotic-assisted TAVR system [2][3] - The TaurusTrio aortic valve replacement system, GeminiOne, and the non-glutaraldehyde cross-linked TAVR product TaurusNXT are expected to be approved and commercialized between late 2025 and 2026, driving revenue growth [2][3] Neurointervention Business - The company has successfully launched the YonFlow mesh stent and has entered multiple provincial markets, indicating strong commercialization potential [4] - The neurointervention business is expected to maintain rapid growth, with a profit margin exceeding 20% and ongoing product development [4] Financial Outlook - The company projects revenues of CNY 758 million, CNY 1.035 billion, and CNY 1.385 billion for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 23.17%, 36.46%, and 33.88% [6] - The net profit attributable to the parent company is expected to improve significantly, with projections of CNY -114 million, CNY 14 million, and CNY 129 million for the same years, reflecting substantial growth [6]